Cardinal Health Raises FY26 EPS Outlook to at Least $10.00, Highlights Strategic Growth

summarizeSummary

Cardinal Health increased its fiscal year 2026 non-GAAP EPS guidance and reported strong progress in specialty growth and strategic initiatives, including a new partnership with Publix.

check_boxKey Events

• Raised Fiscal 2026 EPS Outlook

  Increased non-GAAP diluted EPS guidance to "at least $10.00" from the previous range of $9.65 to $9.85, signaling strong performance.

• Accelerating Specialty Growth

  Expects Specialty revenues to exceed $50 billion in fiscal 2026, representing a 16% compounded annual growth rate over three years, driven by robust demand and BioPharma Solutions growth.

• Successful IRA Transition

  Confirmed successful transition of manufacturer distribution service agreements for all branded pharmaceutical products impacted by the 2026 Medicare Drug Price Negotiation Program.

• New ContinuCare™ Pathway Program

  Launched an innovative direct-to-patient program to simplify diabetes supply management, securing a key partnership with Publix Super Markets Inc. for nearly 1,400 pharmacies.

auto_awesomeAnalysis

Cardinal Health's updated fiscal year 2026 non-GAAP EPS outlook, now "at least $10.00" from a prior range of $9.65 to $9.85, signals strong operational performance and management confidence. This positive revision, coupled with significant strategic progress in specialty growth, successful navigation of IRA changes, and the launch of a new diabetes supply management program with a major partner like Publix, indicates robust business momentum. Investors should view this as a positive indicator of the company's ability to execute its growth strategy and manage regulatory changes effectively.